Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Recruiting now · Phase 1/Phase 2

Conditions studied: Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH)

In brief

Extranodal NK/T-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes with no standard therapy. Notably, 10%-20% of patients develop secondary hemophagocytic lymphohistiocytosis (NKTCL-HLH), a life-threatening complication with median survival \<2 months and mortality over 90%. Current treatments fail to simultaneously control lymphoma and hyperinflammation, with poor tolerance and high resistance. The JAK/STAT pathway drives EBV-induced inflammation and tumor progression. Golidocitinib, a selective JAK1 inhibitor, demonstrates potent anti-NKTCL activity and rapid inflammation control. Liposomal mitoxantrone offers targeted efficacy with lower toxicity, while etoposide, methylprednisolone, and pegaspargase provide synergistic anti-tumor and anti-HLH effects. This study proposes the novel MEPL-G regimen (liposomal mitoxantrone, etoposide, methylprednisolone, pegaspargase, golidocitinib) for NKTCL-HLH. By targeting both HLH and NKTCL, this combination aims to achieve rapid disease control, improve tolerance, and prolong survival, addressing the unmet critical clinical need for this high-risk population.

Key facts

Study ID: NCT07525466
Run by: Beijing Tongren Hospital
People needed: 25
Starts: 2026-04-01
Expected to finish: 2028-09-30
Last updated by the study team: 2026-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Histologically confirmed extranodal NK/T-cell lymphoma.
Meeting the HLH-2004 diagnostic criteria (≥ 5 criteria).
Age ≥ 18 years, regardless of gender.
Negative HIV antigen or antibody.
Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac echocardiography.
No active visceral bleeding (e.g., gastrointestinal, pulmonary, cerebral).
No uncontrolled infection (e.g., pulmonary infection, intestinal infection).
Negative HCV antibody; or positive HCV antibody with negative HCV RNA.
Negative HBsAg and negative HBcAb. If either is positive, peripheral blood HBV DNA load must be < 1×10³ copies/mL to be eligible.
Signed written informed consent and ability to understand and comply with all study requirements.

You may not qualify if…

New York Heart Association (NYHA) cardiac function class ≥ II;
Female patients who are pregnant or breastfeeding;
Known hypersensitivity to any of the study drugs;
Presence of other concurrent malignancies (except non-melanoma skin cancer);
Concurrent central nervous system lymphoma infiltration;
Severe psychiatric disorders or inability to comply with follow-up;
Severe renal dysfunction (glomerular filtration rate < 15 mL/min);
Severe liver cirrhosis (MELD score > 20);
History of acute or chronic pancreatitis;
Simultaneous participation in another clinical trial.

Where it is running

Beijing Tongren Hospital, Capital Medical University — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.